Recent accumulated data have indicated that angiogenesis is a promising indicator to predict prognosisand response to treatment. In breast cancer, microvessel density (MVD), a semi-quantitative markerof neovascularization grade, has been suggested to provide independent prognostic value. In addition, the expression of both vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP), twoangiogenesis regulatory molecules, were found to be closely associated with MVD, and with the effect oftreatments. In particular, VEGF expression seems to be a phenotype resistant to endocrine therapy, whereas TP expression decreases sensitivity to chemotherapy containing fluorouracil. This review summarizesthe current topics regarding the prognostic and predictive value of angiogenesis in primarybreast cancer, and we discuss future applications of antiangiogenesis treatments in an adjuvant setting.